Please login to the form below

Not currently logged in
Email:
Password:

Memorial Sloan Kettering

This page shows the latest Memorial Sloan Kettering news and features for those working in and with pharma, biotech and healthcare.

Sanofi signs $1bn licence agreement for Eureka’s novel multiple myeloma drug

Sanofi signs $1bn licence agreement for Eureka’s novel multiple myeloma drug

Multiple myeloma is the second most common blood cancer. Sanofi has announced a new licence agreement, potentially worth up to $1bn, with US biotech company Eureka Therapeutics and the Memorial Sloan ... Kettering Cancer Center (MSK) for a novel multiple

Latest news

More from news
Approximately 1 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    Strategies for sourcing external innovation include collaborations with universities and leading academic research centers based on their research focus (eg, oncology companies partnering with Memorial Sloan Kettering Cancer Center) and geographic

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    He also cited an FDA-approved TMB test developed by Foundation Medicine and Memorial Sloan Kettering Cancer Center as an example.

  • Deal Watch September 2016 Deal Watch September 2016

    No other financial details were disclosed. Fate Therapeutics entered a three year arrangement with Memorial Sloan Kettering Cancer Center to use engineered pluripotent cell lines to develop T cell product candidates.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • ICR appoints Kristian Helin as its new chief executive ICR appoints Kristian Helin as its new chief executive

    Helin will join ICR in September from the Memorial Sloan Kettering Cancer Center in the US. ... Helin will join the ICR from Memorial Sloan Kettering Cancer Center in the US, where he currently serves as chair of the cell biology programme and director

  • Lilly appoints Maura Dickler as VP of late phase oncology development Lilly appoints Maura Dickler as VP of late phase oncology development

    She will join the pharma firm from the Memorial Sloan Kettering Cancer Center. ... She will move to the pharmaceutical company from the prestigious Memorial Sloan Kettering Cancer Center, where she currently serves as associate member, Breast Medicine

  • José Baselga joins BMS’ board of directors José Baselga joins BMS’ board of directors

    Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and

  • OncoMed’s CMO steps down OncoMed’s CMO steps down

    Prior to this, Dr Dupont was director of early and late stage development at Genentech, and served as a researcher in tumour immunology at the Memorial Sloan Kettering Cancer Center.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Getting personal with wearable tech

    In July 2016, a prestigious US cancer centre, The Memorial Sloan Kettering Cancer Center (MSK), announced their plans to evaluate wearables and other mobile technology to assess cancer patients' quality of

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios - Medical Animation

MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...